ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway

ABSTRACT: Primary objectives: To determine whether adjuvant treatment with 160 mg ASA once daily for 3 years can improve Time To Recurrence (TTR) in patients with colorectal cancer with somatic alterations in the PIK3CA (exon 9 and 20) compared with placebo. Primary endpoints: Time To Recurrence (TTR) at 3 years in patients with tumors harboring PIK3CA mutations in exon 9 and 20.

DISEASE(S): Colon Or Rectal Cancer Tumor Stage Ii-iii, Tumor With Somatic Alterations In Pik3ca, Pik3r1 Or Pten.

PROVIDER: 2534988 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR